The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use

David M. Haas, Amalia S. Lehmann, Todd Skaar, Santosh Philips, Catherine L. McCormick, Kyle Beagle, Scott J. Hebbring, Jessica Dantzer, Lang Li, Jeesun Jung

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Objective: To determine the impact of maternal and fetal single nucleotide polymorphisms in key betamethasone pathways on neonatal outcomes. Study Design: DNA was obtained from women given betamethasone and their infants. Samples were genotyped for 73 exploratory drug metabolism and glucocorticoid pathway single nucleotide polymorphisms. Clinical variables and neonatal outcomes were obtained. Logistic regression analysis using relevant clinical variables and genotypes to model for associations with neonatal respiratory distress syndrome was performed. Results: One hundred nine women delivering 117 infants were analyzed. Sixty-four infants (49%) developed respiratory distress syndrome. Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6). Conclusion: Maternal and fetal genotypes are independently associated with neonatal respiratory distress syndrome after treatment with betamethasone for preterm labor.

Original languageEnglish (US)
Pages (from-to)447.e17-447.e24
JournalAmerican Journal of Obstetrics and Gynecology
Volume206
Issue number5
DOIs
StatePublished - May 2012

Keywords

  • betamethasone
  • neonatal respiratory distress syndrome
  • pharmacogenetics
  • preterm birth

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use'. Together they form a unique fingerprint.

  • Cite this

    Haas, D. M., Lehmann, A. S., Skaar, T., Philips, S., McCormick, C. L., Beagle, K., Hebbring, S. J., Dantzer, J., Li, L., & Jung, J. (2012). The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. American Journal of Obstetrics and Gynecology, 206(5), 447.e17-447.e24. https://doi.org/10.1016/j.ajog.2012.02.016